Novo Nordisk A/S has been spending huge sums to boost manufacturing capacity to meet demand for its GLP-1 drugs and the Danish major's latest megabucks investment is good news for workers in the US but a major blow for Ireland.
Marking "one of the largest manufacturing investments in Novo’s history," the Copenhagen-based group has announced plans to invest $4.1bn to build a second fill and finishing facility in Clayton, North Carolina "to grow its ability to produce current and future injectable treatments for people with obesity and other serious chronic diseases